J Eur Acad Dermatol Venereol. 2021 Jul 17. doi: 10.1111/jdv.17525. Online ahead of print.
ABSTRACT
BACKGROUND: Cross-cultural differences in healthcare policies and patient-physician communication may influence the quality of care and patients’ perceived benefits and satisfaction with psoriasis treatment.
OBJECTIVES: To compare the disease burden and patient needs at baseline, and patient benefits and satisfaction with secukinumab treatment across Europe.
METHODS: PROSE was an open-label, prospective, non-randomised, stratified multicentre study of 52 weeks of secukinumab treatment, in 16 European countries. Secondary analysis of the PROSE study data by European regions was performed to identify cross-cultural differences in disease burden and patient needs at baseline, and in clinical improvement, patient-reported treatment benefits and satisfaction at 52 weeks post-treatment.
RESULTS: At baseline, Dermatology Life Quality Index impairment was reported to be greater in patients from Eastern Europe (EE:15.4±7.1) versus Northern Europe (NE:13.3±6.7) and Western Europe (WE:13.6±6.9), but while differences were statistically significant (F-test=5.5, p<0.001), their clinical significance is uncertain. There were no significant differences between regions in Psoriasis Area and Severity Index at baseline (F-test=1.6). There were considerable differences in patients’ needs (Patient Need Questionnaire) between geographical regions, with WE focused more on reducing physical impairment versus Southern Europe [SE]/EE), EE on reducing social impairment (versus NE/WE), and SE on reducing impairment due to therapy (versus NE/WE). At Week 52, patients from EE reported more benefits (Patient Benefit Index) with secukinumab treatment (versus WE/SE), while patients from NE reported higher global treatment satisfaction (versus SE).
CONCLUSIONS: Differences in patients’ needs and treatment satisfaction across Europe are likely a result of diverse medical systems, socio-economic status and infrastructural access. A patient-centred approach to treating psoriasis may fulfil patient needs and maximise treatment satisfaction. (NCT02752776).
PMID:34273904 | DOI:10.1111/jdv.17525
